Mr. Hayakawa was appointed as our board director
Raised 1.6 billion yen through third-party allotment to prepare for clinical trials of ASCL-PLC
Concluded a basic agreement with H.U. Cells, Inc. regarding contracted business for PRP therapy
Notice of Management Change
Raised JPY 152 million through third-party allotment for the early commercialization of ASCL-PLC, a...
The disclosed information of the clinical study has been updated
AdipoSeeds raised 4 million JPY
AdipoSeeds received an acceptance about the compliance of the clinical study to the guideline for t...
The paper of ASCL-PLC was adopted as Plenary Paper of Blood
The patent of manufacturing platelets from adipose tissue-derived mesenchymal stem cell was registe...
AdipoSeeds became an affiliated institution for the research program funded by AMED